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Abstract
Background: Due to the increasing prevalence of Mycobacterium tuberculosis strains resistant to one or more
antibiotics, there is a need for new quantitative culture methods both for drug susceptibility testing and for
validation of mutations putatively associated with drug resistance. We previously developed a (myco) bacterial
culture method, in which multiple growing microcolonies are monitored individually. Transfer of the growing
microcolonies to selective medium allows the effect on the growth rate of each individual colony to be
determined. As entire growing colonies are exposed to antibiotics rather than re-subbed, a second lag phase is
avoided and results are obtained more rapidly. Here we investigate the performance of the microcolony method to
differentiate between ethambutol (EMB) resistant, intermediate and susceptible strains.
Methods: One week old microcolonies from a reference panel of four strains with known EMB susceptibility were
transferred to different concentrations of EMB. Growth rates during the 1st 2 days of exposure were used to set up
classification criteria to test and classify a blinded panel of 20 tuberculosis strains with different susceptibilities.
Results: For 18 strains (90%) reference culture results corresponded to our classifications based on data collected
within 9 days of inoculation. A single strain was classified as Intermediate instead of Susceptible, and 1 strain could
not be classified due to a contamination.
Conclusions: Using a microcolony growth monitoring method we were able to classify, within 9 days after
inoculation, a panel of strains as EMB susceptible, intermediate or resistant with 90% correlation to the reference
methods.
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Background
The increasing prevalence of Mycobacterium tuberculosis
strains resistant to one or more antibiotics makes drug
susceptibility testing (DST) a high priority. The rapid
molecular detection of resistance e.g. for rifampicin
(RIF) by automated molecular methods [1] creates an
additional demand for phenotypic susceptibility testing
to other agents. In fact a complete prediction of the
in vivo susceptibility of strains to available drugs is
desired both to ensure the provision of the least toxic
and most effective therapy to the individual patient and
for interrupting the transmission of drug resistant path-
ogens. For some drugs this is difficult to achieve with
the standard, at most semi-quantitative culture methods
currently in use.
Unfortunately DST for tuberculosis (TB) is too slow,
complex or dangerous to be effectively implemented in all
settings, therefore novel strategies with the potential to be
automated warrant investigation [2]. We have previously
described an in-house (myco) bacterial culture method
[3], in which the growth of microcolonies from individual
colony forming units (CFUs) is monitored similar to the
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ScanLag system [4]. But in addition, in our system the
microcolonies can be transferred to different media
whilst monitoring their growth. Thus, it is possible to
determine the susceptibility of growing colonies to a
drug by measuring the change in growth rate after expos-
ure. As each individual colony is monitored, detection of
multiple phenotypes, for example a mixed resistant and
susceptible bacterial population (heteroresistance), is
possible [3].
Detection of RIF susceptibility and resistance in Myco-
bacterium tuberculosis lab strains was previously achieved
within 8 days after inoculation and only 24 hours after
exposure to RIF [3]. Transferring intact growing colonies
onto selective medium during their exponential growth
phase avoids the second lag phase and thus is more rapid
than classical subculturing selected colonies onto plates
or into liquid medium containing antibiotics. Also, as
individual microcolony growth rates can be accurately
monitored, more subtle effects may be detected such
as partial inhibition. This may aid the identification of
clinically significant resistance in strains that (due to an
MIC close to the breakpoint concentration) is more diffi-
cult to detect using traditional methods. Also the ability of
the system to detect more subtle in vitro responses to
antibiotic challenge may allow the detection of additional
phenotypes with altered response to in vivo therapy.
Therefore, we investigated the capacity of our microcolony
approach for DST of a more challenging antibiotic
Ethambutol (EMB).
Standard methods for DST are based on either the
proportion method and performed on solid media, or on
critical concentration assays performed in liquid culture
systems [5]. More recently the observation of cording/
“microcolony” formation in liquid media in the Micro-
scopic Observation Drug Susceptibility assay (MODS)
has been applied [6,7].
For some antimycobacterial drugs such as isoniazid
and RIF, the agreement between different methods and
between different labs is very good , but for EMB, even
in well-established labs susceptibility testing remains
challenging [8,9], possibly because the minimal inhibi-
tory concentrations (MICs) of both wild type and EMB
resistant strains are close to the recommended critical
concentration [10]. Therefore maintaining reproducibility
becomes more difficult than for antibiotics such as RIF,
for which the majority of resistant strains have a MIC
far above the breakpoint concentration [11,12].
Also, susceptibility testing against EMB does not correl-
ate well with the known molecular markers of EMB resist-
ance thus molecular testing produces results that are
difficult to interpret. A number of mutations have been as-
sociated with EMB resistance, predominantly in embCAB
[13,14], but their association with resistance is not strong
enough to classify strains as susceptible or resistant [14].
Here we investigate the performance of the microcolony
method to differentiate between EMB resistant, intermedi-
ate and susceptible strains. Using four strains with known
EMB susceptibility/resistance we determined microcolony
growth classification criteria. Then the growth of microco-
lonies from a blinded panel of 20 TB strains was moni-
tored and these strains classified using our classification
criteria. Results were then compared to classical suscepti-
bility testing performed in a reference laboratory.
Methods
Strains
A panel of 24 TB strains was received by the Royal
Tropical Institute from the Swedish Institute for Com-
municable Disease Control (SMI) on Lowenstein Jensen
slopes (Table 1). Strains were coded 1–24 and from strains
1–4 the susceptibility testing results were provided to
serve as reference. Strain 1 was labeled susceptible (S),
strain 2 intermediate (I) and strains 3 and 4 resistant
(R). No information was provided from strains 5–24
prior to communication of the results to the SMI.
All strains were inoculated in Middlebrook (MB) 7H9
medium (Difco, BD, Sparks, MD, USA) + OADC (BBL,
BD) and subcultured every 3–4 weeks.
To control laboratory procedures multiplex ligation-
dependent probe amplification (MLPA) [15] was per-
formed on DNA isolated from the 1st routine cultures
and from the last subcultures after testing of the panel,
this yielded identical results for all (45) resistance asso-
ciated markers and lineage type markers for all individ-
ual strains (data not shown).
DST performed with BACTEC MGIT 960 and Middlebrook
proportion method
Strains were tested to 4 and 8 mg/L EMB (Sigma-Aldrich,
Stockholm, Sweden) using the Middlebrook 7H10 agar
proportion method as earlier described [10] or to 2.5 and
5 mg/L using the BACTEC MGIT 960 system (Becton
Dickinson, Sparks, MD).
For the BACTEC MGIT, the DST inoculum was pre-
pared from bacterial growth on Löwenstein-Jensen egg
medium in 37°C. Briefly, two 1 μL-loops of bacteria were
suspended in 3 ml of phosphate buffered saline (PBS) in a
small glass tube with glass beads. Homogenization of the
bacterial suspension was obtained by vortexing or in an
ultrasound water bath to disperse clumps. Thereafter the
suspension was left to sediment for 20 min and the upper
2 mL were transferred to a new tube and let to sediment
for another 15 min.
Prior to inoculation of the BACTEC MGITculture tubes
the bacterial suspension was adjusted to a McFarland
turbidity of 0.5 and diluted in PBS according to the test
protocol from the manufacturer. The drug susceptibility
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to the recommended critical concentration of 5 mg/L
EMB was assessed using the Becton Dickinson kit.
Strains were determined EMB susceptible when the
growth unit (GU) of the culture tubes containing 2.5-
5 mg/L EMB were ≤100 when the 1:100 diluted drug
free control had reached GU = 400. Strains growing at
concentrations between 2.5 and 5 mg/L were considered
intermediary (I) resistant.
Microcolony growth monitoring
Microcolony growth was performed in 4-well culture
plates (Nunc multidish 4 SI, Nunc A/S, Denmark), on
squares of porous aluminium oxide (PAO, Whatman,
Kent, UK) on top of MB7H10 agar (Difco, BD, Sparks,
MD, USA) +OADC. Agar was prepared in standard petri
dishes, and disks punched out of the agar were transferred
to the 4-well culture plates. Strips of 3.6×0.8 cm PAO were
sterilized by submerging in 100% ethanol and cut into 4
squares of approx. 0.8×0.8 cm. After evaporation of the
ethanol PAO squares were wetted in sterile water and placed
on MB7H10 +OADC agar in the 4-well culture plates.
Mycobacterial cultures were vortexed for 20s and sedi-
mented for at least 15 min. A 2 ml aliquot of the suspen-
sion was filtered through a 5 μm filter (Whatman) to
obtain a suspension of single cells. Cells were diluted in
MB7H9 to approx. 3× 106 cells/ml based on the assump-
tion that an OD450 of 0.15 corresponds to 10
8 cells/ml.
Three μl of this suspension was inoculated on the squares
of PAO. Plates were incubated at 36°C.
A stock solution of 4 mg/ml EMB in water was pre-
pared and stored aliquoted at −20°C. Four-well plates
with MB7H10 agar + OADC supplemented with differ-
ent concentrations of EMB (Ethambutol dihydrochlor-
ide, Sigma-Aldrich, St. Louis, MO, USA) were prepared
as described above and used within 9 days.
Initially, growth of all 24 strains on non selective
medium was monitored between days 5 and 16 or until
the colonies covered the surface to determine the time
Table 1 Classification of the tested strains
strain SMI Strain number Threshold concentration (mg/L) † Microcolony growth-based classification (This study) SMI classification
1 XTB 10-172 1 S S
2 XTB 09-045 4 I I
3 XTB 09-023 16 R R
4 XTB 09-060 16 R R
22# XTB 09-060 >8 R R
24# XTB 09-060 >8 R R
5 XTB 10-167 ≤1 S S
6 XTB 10-166 4 I S
7 XTB 10-158 ≤2 S S
8 XTB 09-109 >8 R R
9 XTB 09-108 8 I/R* I
10 BTB 09-554 >8 R R
11 BTB 11-250 4 I I
12 BTB 11-214 >4 R R
13 BTB 11-145 2 S S
14 BTB 11-421 2 S S
15 XTB 10-170 >8 R R
23# XTB 10-170 >4 R R
16 BTB 11-416 4 I S/I
17 BTB 11-417 ≤1 S S
18 BTB 11-418 ≤1 S S
19 BTB 11-419 ≤1 S S
20 BTB 11-420 ≤1 S S
21 BTB09-553 >4 R R
Strains 1–4: reference strains, strains 5–24: blinded strains. † Threshold concentration, lowest concentration tested at which >40% reduction in growth rate
compared to control (no EMB) was recorded. Where 40% reduction in growth rate was reached at the lowest concentration tested a ≤ symbol precedes the
concentration, Where the threshold was not reached at the highest concentration tested, this is indicated by a > symbol. *4 mg/L missing due to contamination.
When retested, strain 9 was correctly classified as intermediate. # Strains 22 and 24, and strain 23 were (unknown) duplicates of strain 4 and 15, respectively.
The 2 results discordant between the microcolony growth-based classification and the SMI classifications are indicated in boldface.
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frame for the EMB exposure experiments. Based on the
results of experiments, exposure experiments to EMB
were set up as follows:
For the four reference strains 1–4 eight squares of
PAO were inoculated and grown for 7 days on non-
selective medium. The PAO squares containing microco-
lonies were manually transferred to 0; 0.5; 1; 2; 4; 5; 8
and 16 μg/ml EMB. Using an automated microscope
system (Muscan, CCM BV, Nuenen, The Netherlands),
images were recorded at 5 and 7 days after inoculation
(pre-exposure baseline), directly after transfer (exposure
to EMB began 7 days after inoculation) and then after 2,
5, 7 and 9 days of EMB exposure (corresponding with
days 7, 9, 12, 14 and 16 after inoculation). Imaging was
terminated at 16 days or if single colonies could no
longer be discriminated due to overgrowth.
Based on the results of the four reference strains 1–4
(Figures 1 and 2) it was decided to test the blinded panel
using the same conditions and transfer on day 7, except
that exposures were limited to concentrations of 0; 1; 2;
4 and 8 μg/ml EMB. Imaging was performed at the same
time points as above.
Image and data analysis
Image analysis was performed essentially as described in den
Hertog et al. [3], but using a second generation microscope
system (Muscan) allowing for higher throughput, and
another software package with additional tools (FIJI; [16]).
Microcolony microscopy was performed using an au-
tomated microscopy system (Muscan) with bright field
imaging, coaxial illumination, and a 5 × objective. Im-
ages were recorded with a monochrome CCD camera
(XCD-SX90, Sony, Tokio, Japan; with field size 1280×960
pixels). From each well at each time point a set of 81
images (9 by 9 images of 0.95 × 0.71 mm each with an
overlap of approx. 5.6% and 16.2% in X and Y direction
respectively) was collected covering a total area of approx.
8.0 × 5.5 mm.
Using FIJI, first the set of 81 photos recorded per PAO
square were stitched into a single image using the
“Stitching 2D/3D” plugin [17]. Next, all stitched TIF im-
ages of the same PAO taken at the different time points
were stacked and registered using the “Linear stack
alignment with SIFT” plugin [18] to align potential col-
onies over all time points. Standard settings were used
Figure 1 Growth rates of the reference strains 1 (A), 2 (B), 3 (C) and 4 (D) before and after transfer to EMB. Note that the control of strain 1
was fully grown at day 12, thus control growth rate could not be calculated beyond the 2nd day of exposure. Average and standard deviations are shown.
Data from strain 2 exposed to 1, 5 and 16 mg/L EMB and from strain 4 exposed to 0 and 8 mg/L EMB are missing due to contamination.
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except the minimum and maximum image size for the
scale invariant Interest point detector were set at 200
and 3000 respectively.
Macros were written to perform the following steps in
FIJI: first a background reduction (with rolling ball ra-
dius of 200 pixels) and a 2 pixel radius median filter
were applied. Next, using the “RenyiEntropy” method
the images were converted to binary with a threshold
level of 238. Using the “Analyse particles” tool the sizes
and XY coordinates of all particles with a minimal size
threshold of 50 pixels and a circularity of or above 0.5
were saved into a text file.
The data extracted from the images was then processed
using the web application described by den Hertog et al.
[3] to identify particles with equivalent XY coordinates
present in at least two sequential time points. The sizes of
the resulting lists of objects at sequential time points were
exported to excel for further analysis. On basis of this
information individual colony growth rates, defined as %
increase in surface area/day, were calculated for all strains
and conditions between sequential time points.
Objects that fulfilled the following were identified as
mycobacterial colonies:
– An increase in surface area of the object of >20%
per day between days 5 and 7 after inoculation.
– No significant effect of transfer on the objects
surface area (<20% change); i.e. similar surface area
of both measurements on day 7 after inoculation
made before and after transfer
– Presence and no decrease in size (<10% per day) of
the object after transfer to selective medium (or
control) days 7 and 9.
Classification
Based on the growth inhibition profiles of the reference
strains 1–4 (See Results section), criteria were defined to
allow the unknown strains to be classified. At each con-
centration of EMB the relative average growth rate com-
pared to the unexposed control (0 mg/L EMB) was
calculated for days 7–9, 0 to 2 days EMB exposure. Strains
were classified based on the lowest EMB concentration
resulting in a decrease in relative growth rate (compared
to the unexposed control) of > 40%; If growth was de-
creased 40% or more at i. concentrations ≤2 mg/L, strains
were classified as Susceptible, ii. 4 mg/L as Intermediate,
iii. if growth rate was reduced less than 40% at >4 mg/L as
Resistant.
Results
Baseline growth rate of strains on non selective medium
Growth of all strains was monitored from 5 days to
16 days after inoculation or until confluence was
reached. The data collected was used to determine for
the EMB exposure experiments at which time points to
measure the baseline and transfer the microcolonies to
EMB. All strains had stable growth rates measured be-
tween days 5–9 and when data was available, between
days 5–12. All strains were thus in the exponential
growth phase between days 5 and 9. Based on data from
629 to 9608 (median 3911.5) microcolonies per strain
the average microcolony surface area between days 5
and 7 after inoculation increased by 45.6% to 114.7% per
day (Figure 3). These growth rates correspond to doub-
ling times of 20.9 to 52.6 hours.
Despite the wide range in growth rates, microcolonies
from all strains were detectable 5 days after inoculation.
Therefore, imaging was begun at day 5 and exposure to
EMB at day 7.
Effects of EMB on the growth of reference strains
To establish criteria to classify the blinded strains, four ref-
erence strains with known EMB susceptibility (susceptible,
intermediate and resistant) were exposed to 0–16 mg/L
Figure 2 Relative growth rates of reference strains (as % of 0 mg/L control) between days 7 and 9 after transfer to EMB on day 7.
*For strain 4 results are shown relative to the pre-exposure growth rate due to contamination of the control. Error bars represent the standard
deviation of the relative growth rate of individual microcolonies.
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EMB from day 7 after inoculation and growth curves for
individual microcolonies were produced (Figure 1).
The growth rate of the susceptible strain 1 was approxi-
mately halved by the presence of 1 mg/L EMB within the
1st 2 days of exposure (days 7–9). After day 9 (2 days EMB
exposure) the growth of strain 1 was completely inhibited
by concentrations higher than 4 mg/L (Figure 1A). In con-
trast, the growth rate of intermediate resistant strain 2 was
unaffected by the presence of up to 2 mg/L EMB for the
1st 5 days of exposure (day 12) but clear inhibition was
seen for concentrations over 4 mg/L EMB from day 7 on-
wards (Figure 1A). The growth rate of resistant strains 3
and 4 was only reduced by 16 mg/L of EMB when com-
pared to the antibiotic free control or the pre-exposure
growth rate (Figure 1C-D).
The data collected between days 7 and 9 presented in
Figure 1 was used to calculate the relative growth rates
compared to the unexposed controls (0 mg/L for all
EMB concentrations) for each strain (Figure 2). Based
on this analysis it was decided to expose the strains in
the blinded panel to 0; 1; 2; 4 and 8 mg/L EMB. Further-
more a classification scheme was established as follows:
Strains with a decrease in growth rate compared to the
unexposed control between 0–2 days of exposure of
more than 40% at <2 mg/L were classified as susceptible,
a decrease in growth rate of >40% between 2–4 mg/L as
intermediate, and a decrease in growth rate of <40% at
4 mg/L as resistant. The resulting classification was then
reported to the reference laboratory and only then the
code broken.
Using the microcolony method eight strains were
classified as susceptible (Figure 4A, Table 1), three
strains as intermediate (Figure 4B) and eight strains as
resistant (Figure 4C). Classification of strain 9 was uncer-
tain (between intermediate and resistant Figure 4B-C)
due to missing data, contamination of the 4 mg/L PAO
filter. Upon breaking the code and comparing to the
classification and MICs of the strains as determined
by the Swedish Institute for Communicable Disease
Control (Table 1) all resistant strains (strains 8, 10, 12,
15, 21, 22, 23 and 24) were found to have been correctly
identified. Classification of the remaining strains all
with a MICs below the breakpoint concentration of
5 mg/L was in agreement (intermediate or susceptible)
by both methods except for strain 6 which was identified
as intermediate by the microcolony method and suscep-
tible by the reference laboratory (Table 1) and strain 9
which was not grouped due to missing data. Retesting of
strain 9 after breaking the code resulted in corresponding
classification as intermediate (data not shown).
Frequency distributions of the relative growth rates
between days 7–9 of the exposed microcolonies showed
homogeneous responses in all conditions for every strain
(Additional file 1).
Figure 3 Growth rates (% increase in surface area per day) of strains 1–24 between days 5 and 7 after inoculation. Pre-exposure data
from the EMB exposure experiments (black bars), and data collected in the baseline experiments (white and grey bars) are combined. Diamonds
represent the weighted average of all data points for each strain, ranging between 629 and 9608 (median 3911.5) data points per strain.
*As shown in Table 1, strains 22 and 24 are the same strain as strain 4, and strain 23 is the same as strain 15, although they were included as
individual strains in the blinded panel. Error bars represent the standard deviation of the growth rate of individual microcolonies.
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Discussion
EMB susceptibility testing of M. tuberculosis isolates is
challenging and difficult to perform reproducibly [19].
Here we have shown that with our microcolony growth
monitoring method exposure of growing microcolonies
to EMB can provide clear and accurate EMB susceptibil-
ity determinations within 2 days of exposure (9 days
after initial inoculation). In this study the growth of a total
of more than 100,000 automatically identified microcolo-
nies was tracked.
A blinded panel of 20 strains was tested, 18 of which
were classified by our method into identical groups as the
reference laboratory using the gold standard method. One
strain (strain 6) classified by our method as intermediate
was classified as susceptible by the reference laboratory.
Another strain (strain 9) could not be classified more
accurately than “Intermediate or Resistant” from the initial
blinded testing due to laboratory contamination of the
4 mg/L exposure (Figure 4) , although when retested after
breaking the code it was correctly classified as Intermedi-
ate by the microcolony method (not shown).
We classified the strains on the basis of % growth inhib-
ition compared to an antibiotic free control at 2 concen-
trations (2 and 4 mg/L of EMB). However our method
results in an unprecedented amount of data and it may be
possible, if growth conditions are carefully selected, to de-
termine EMB susceptibility by testing at single time point
with only a single concentration. For example, after break-
ing the code we realized that the relative growth rate after
48 hours on 2 mg/L alone would have been sufficient to
classify 17 out of 20 strains identically to the reference
method (by classifying strains as sensitive strains with a
relative growth rate <60%, strains as intermediate with a
growth rate between 60 and 80%, and strains as resistant
with a growth rate of >80% of the control (Figure 4)). Also
in this study we decided to classify after 2 days of EMB
exposure but findings of de Steenwinkel et al. [20] demon-
strate that EMB inhibition in liquid cultures is detectable
Figure 4 Classification of the blinded panel of strains as susceptible (A), intermediate (B) or resistant (C) based on their relative
growth rates on EMB containing medium between day 7–9. *Strain 9 could not be classified between I and R due to missing data due to
contamination of the sample exposed to 4 mg/L EMB and is shown in both I and R graphs. The 0 mg/L control of strain 19 was contaminated,
therefore pre-exposure growth rate was used as 100% for this strain. When retested (not shown) results for strain 19 were similar.
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within 24 Hours. As our method can also detect subtle
changes in growth we believe classification may have been
possible after only 1 days exposure to EMB.
A number of mutations, predominantly in the embB
gene, associated with EMB resistance have been identified,
but the correlation with susceptibility testing is low [21,22]
making the clinical significance of the mutations based on
classical phenotypic testing results difficult to determine
[23]. In a recent study [24], the spectrum of EMB resist-
ance associated mutations has been expanded with other
genes involved in decaprenylphosphoryl-β-D-arabinose
(DPA) biosynthetic and utilization pathways both in vitro
and in vivo. The authors demonstrate that resistance is
acquired or increased step-wise, and multiple mutations in
different genes including embCAB are required to obtain
high level resistance. The broad spectrum of mutations
that diversely affect the susceptibility explains the difficulty
of phenotypic testing for EMB when compared to some
other antibiotics for which the number of (identified) rele-
vant resistance conferring mutations are limited and their
effect on the MIC is dramatic. This results in poorer agree-
ment between DST from different labs for EMB compared
to other antibiotics such as RIF and isoniazid [10,19].
We have shown that inhibition of growth is not always
complete, which would be an additional complication for
traditional DST assays that can yield a positive or negative
result at each concentration. For instance, the intermedi-
ately susceptible strain 2 continues to grow for at least
10 days with a constantly reduced growth rate of approx.
50% on 4 mg/L EMB (Figure 1). This partial inhibition
was confirmed to be due to reduced growth rate of all col-
onies and thus is not an artifact due to heteroresistance
(eg. a mixed genotype), which would have been detected
as a proportion of colonies growing at the normal rate and
a proportion completely inhibited (not shown, except for
days 7–9 in Additional file 1).
The large numbers of mutations involved in EMB resist-
ance make the development of accurate molecular assays
for detecting resistance associated mutations as proxy
for phenotypic susceptibility a huge challenge. In order to
model the subtle effects of the different mutations on sus-
ceptibility to EMB, accurate measurement of the inhibition
of growth rate of a statistically robust number of colonies
in the presence of EMB may be more informative than only
the MIC value resulting from traditional culture methods.
For this study, our data analysis treated all colonies from
a single exposure as a homogeneous population, which
was confirmed to be true based on the frequency distribu-
tions of growth rates between days 7–9 (Additional file 1).
However, as the number of colonies analyzed per condi-
tion is large (generally >100), and analysis based on the
frequency distributions of growth rates would be a power-
ful tool for detecting heteroresistance or confirming a
single phenotype as was the case in this study.
Presently our method requires the careful manipula-
tion of the PAO filters containing growing microcolonies
and a simple device to facilitate this step will be required
before the method can be widely adopted. Current we
and our partners are working on the development of
such a device as well as integrating our image analysis
method into a user friendly microscopic reader with in-
tegrated software in order to make a system available to
other researchers and more suitable to high throughput
applications.
Conclusion
In conclusion, monitoring of multiple microcolonies al-
lows rapid determination of EMB susceptibility and has
applications in diagnostics and for characterization of
the inhibitory effect of EMB on strains carrying resist-
ance associated mutations.
Additional file
Additional file 1: Frequency distributions of relative growth rates
of strains 1–24 between days 7–9. Frequency distributions of the
growth rate relative to the averaged unexposed 0 mg/L control are
shown for each strain. Distributions are shown with 20% bins, and data
are plotted at the upper limit of each bin. (e.g. data over 80-100% is
plotted at 100%). Frequency is expressed as the % of total counts.
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